PMID- 30636390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2383-7837 (Print)
IS  - 2383-7845 (Electronic)
IS  - 2383-7837 (Linking)
VI  - 53
IP  - 2
DP  - 2019 Mar
TI  - Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an 
      Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
PG  - 86-93
LID - 10.4132/jptm.2018.12.26 [doi]
AB  - BACKGROUND: Both human leukocyte antigen (HLA) class I and programmed 
      death-ligand 1 (PD-L1) molecules are known to play important roles in cancer 
      immunity. In this study, we evaluated HLA class I expression in resected 
      adenocarcinoma of the lung, and investigated its prognostic impact in correlation 
      with PD-L1 expression. METHODS: HLA class I and PD-L1 expression was evaluated by 
      immunohistochemistry in a total of 403 resected lung adenocarcinomas using tissue 
      microarray. Correlations between the expression of HLA class I/PD-L1 and 
      clinicopathologic features and prognostic significance were analyzed. RESULTS: 
      HLA class I expression was reduced in 91.6% of adenocarcinoma, and more 
      frequently reduced in patients with younger age, absence of vascular invasion, 
      and low pathologic stage (p = .033, p = .007, and p = .012, respectively). 
      Positive PD-L1 expression in tumor cells was 16.1% (1% cut-off), and associated 
      with poor differentiation, presence of vascular invasion and nodal metastasis (p 
      < .001, p = .002, and p = .032, respectively). On survival analysis, HLA class I 
      or PD-L1 expression alone did not show any statistical significance. On the 
      integrated analysis, HLA class I (+)/PD-L1 (+) subgroup showed a significantly 
      shorter overall survival than other groups (p = .001). Multivariate analysis 
      revealed that coexpression of HLA class I and PD-L1 was an independent poor 
      prognostic factor of lung adenocarcinoma. (p < .001; hazard ratio, 6.106; 95% 
      confidence interval, 2.260 to 16.501). CONCLUSIONS: Lung adenocarcinoma with 
      coexpression of HLA class I and PD-L1 was associated with poor prognosis. This 
      subgroup may evade immune attack by expressing PD-L1 protein despite HLA 
      expression.
FAU - Han, Yeon Bi
AU  - Han YB
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Kwon, Hyun Jung
AU  - Kwon HJ
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Park, Soo Young
AU  - Park SY
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Kim, Eun-Sun
AU  - Kim ES
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Kim, Hyojin
AU  - Kim H
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Chung, Jin-Haeng
AU  - Chung JH
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Korea.
LA  - eng
GR  - SNUBH 14-2018- 018/Seoul National University Hospital/
GR  - 2017R1A5A1015626/National Research Foundation of Korea/
GR  - HI17C1290/Ministry of Health and Welfare/
PT  - Journal Article
DEP - 20190114
PL  - Korea (South)
TA  - J Pathol Transl Med
JT  - Journal of pathology and translational medicine
JID - 101650151
PMC - PMC6435990
OTO - NOTNLM
OT  - Carcinoma, non-small cell lung
OT  - Human leukocyte antigen class I
OT  - Immunohistochemistry
OT  - Programmed cell death-ligand 1
COIS- Conflicts of Interest The authors declare that they have no potential conflicts 
      of interest.
EDAT- 2019/01/15 06:00
MHDA- 2019/01/15 06:01
PMCR- 2019/03/01
CRDT- 2019/01/15 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/12/26 00:00 [accepted]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/01/15 06:01 [medline]
PHST- 2019/01/15 06:00 [entrez]
PHST- 2019/03/01 00:00 [pmc-release]
AID - jptm.2018.12.26 [pii]
AID - jptm-2018-12-26 [pii]
AID - 10.4132/jptm.2018.12.26 [doi]
PST - ppublish
SO  - J Pathol Transl Med. 2019 Mar;53(2):86-93. doi: 10.4132/jptm.2018.12.26. Epub 
      2019 Jan 14.